Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMPNASDAQ:BDRXNASDAQ:CPIXNYSE:LCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsBDRXBiodexa Pharmaceuticals$1.03+29.3%$1.29$0.78▼$41.50$37.64M1.211.08 million shs54.85 million shsCPIXCumberland Pharmaceuticals$5.36-0.7%$5.06$1.04▼$7.25$80.19M-0.29863,267 shs13,957 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BDRXBiodexa Pharmaceuticals0.00%-6.36%-21.97%-41.81%+102,999,900.00%CPIXCumberland Pharmaceuticals0.00%-8.53%+6.56%+16.78%+245.81%LCILannett0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABDRXBiodexa Pharmaceuticals0.2852 of 5 stars0.03.00.00.02.40.00.0CPIXCumberland Pharmaceuticals0.8526 of 5 stars0.05.00.00.01.41.70.0LCILannettN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/ABDRXBiodexa Pharmaceuticals 0.00N/AN/AN/ACPIXCumberland Pharmaceuticals 0.00N/AN/AN/ALCILannett 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00BDRXBiodexa Pharmaceuticals$470K80.08N/AN/A$0.29 per share3.55CPIXCumberland Pharmaceuticals$37.87M2.12$0.26 per share20.84$1.61 per share3.33LCILannett$340.58M0.00N/AN/A($23.34) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ABDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/A7/11/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.25N/A∞N/A-7.98%6.92%2.33%8/5/2025 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ALatest LCI, CPIX, BDRX, and ADMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CPIXCumberland PharmaceuticalsN/A$0.15N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19BDRXBiodexa Pharmaceuticals0.011.751.75CPIXCumberland Pharmaceuticals0.181.251.09LCILannettN/A2.231.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%BDRXBiodexa Pharmaceuticals17.51%CPIXCumberland Pharmaceuticals15.51%LCILannett40.28%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%BDRXBiodexa Pharmaceuticals0.34%CPIXCumberland Pharmaceuticals44.85%LCILannett13.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableLCILannett81010.77 million9.35 millionOptionableLCI, CPIX, BDRX, and ADMP HeadlinesRecent News About These CompaniesDespite Recent Weak Spots, LCI Industries Is Still Appealing At Current PricesJanuary 17, 2025 | seekingalpha.comCompleting a successful tech transferAugust 16, 2024 | pharmaphorum.comThe pharma trends leading to higher demand for CDMOsAugust 10, 2024 | pharmaphorum.comLevothyroxine Dosage and the Limitations of Current Bioequivalence StandardsApril 7, 2024 | medscape.com‘We lost a good friend;’ Coweta County deputy ran over, killed by Alabama officer identifiedJanuary 6, 2024 | wsbradio.comInsider Traders Made Easy Money on Stock OfferingsOctober 2, 2023 | tradersmagazine.comLucky Core Industries Ltd.September 20, 2023 | wsj.comLannett (LCI) Stock Sinks on Lowered Guidance, Canaccord DowngradeSeptember 15, 2023 | thestreet.comGeneric-Drugs Antitrust Case Expanded to Include 18 CompaniesAugust 2, 2023 | courthousenews.comLannett official: Bankruptcy won’t affect Seymour facilityMay 12, 2023 | tribtown.comLannett official: Bankruptcy won't affect Seymour facility - Seymour TribuneMay 12, 2023 | news.google.comSocietal CDMO Reports First Quarter 2023 Financial Results - Yahoo FinanceMay 11, 2023 | news.google.comLannett files prepackaged Chapter 11 cases - Drug Store NewsMay 11, 2023 | news.google.comVolunteers complete projects for Jackson County United Way’s 27th ... - Seymour TribuneMay 10, 2023 | news.google.comAround the nation: Biden administration warns against medical ... - The Daily BriefingMay 9, 2023 | news.google.comGlobal Methylphenidate Drug Market Size Emerging Trends and Will ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comGlobal Drugs of UDCA Market Size Analysis, Share, Application ... - The Northwestern ExaminerMay 8, 2023 | news.google.comErgocalciferol Market Statistical Forecast, Trade Analysis 2023 - Sanofi S.A., Orit Laboratories LLC, Lannett - openPRMay 8, 2023 | news.google.comGeneric Drugmaker Lannett Hits Ch. 11 With $700M In Debt - Law360May 5, 2023 | news.google.comPadagis Achieves A US First With Budesonide Foam Launch - Generics BulletinMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCI, CPIX, BDRX, and ADMP Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Biodexa Pharmaceuticals NASDAQ:BDRX$1.03 +0.23 (+29.35%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.01 -0.02 (-1.94%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Cumberland Pharmaceuticals NASDAQ:CPIX$5.36 -0.04 (-0.74%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.38 +0.02 (+0.37%) As of 06/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
